Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Spero Therapeutics, Inc. (NASDAQ:SPRO) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.45 and traded as low as $1.52. Spero Therapeutics shares last traded at $1.57, with a volume of 2,614,231 shares traded.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Spero Therapeutics currently has an average rating of “Reduce”.

Spero Therapeutics Price Performance

The stock has a market capitalization of $90.90 million, a P/E ratio of 6.54 and a beta of 1.49. The stock has a 50 day moving average price of $2.46 and a 200-day moving average price of $2.45.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.26 million. Spero Therapeutics had a return on equity of 35.58% and a net margin of 24.90%.

Insider Buying and Selling

In other Spero Therapeutics news, insider Esther Rajavelu sold 25,240 shares of Spero Therapeutics stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $2.51, for a total value of $63,352.40. Following the transaction, the insider directly owned 986,851 shares of the company’s stock, valued at $2,476,996.01. The trade was a 2.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by company insiders.

Institutional Trading of Spero Therapeutics

A number of institutional investors have recently made changes to their positions in SPRO. Invesco Ltd. bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $43,000. Millennium Management LLC bought a new stake in Spero Therapeutics during the 4th quarter valued at $56,000. Dimensional Fund Advisors LP purchased a new stake in Spero Therapeutics during the 3rd quarter valued at $55,000. XTX Topco Ltd purchased a new stake in Spero Therapeutics during the 2nd quarter valued at $100,000. Finally, Quadrature Capital Ltd bought a new stake in Spero Therapeutics in the 4th quarter worth $88,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.